Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00004584 |
The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632. Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Atazanavir Drug: Ritonavir Drug: Saquinavir |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Dose Comparison, Safety Study |
Official Title: | Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination Regimen(s) as Compared to a Reference Combination Regimen(s) in Antiretroviral-Experienced HIV-Infected Subjects |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients may be eligible for this study if they:
Exclusion Criteria
Patients will not be eligible for this study if they:
Study ID Numbers: | 302B, AI424-009 |
Study First Received: | February 10, 2000 |
Last Updated: | October 1, 2007 |
ClinicalTrials.gov Identifier: | NCT00004584 |
Health Authority: | United States: Food and Drug Administration |
Dose-Response Relationship, Drug Drug Therapy, Combination HIV Protease Inhibitors Ritonavir |
Saquinavir Reverse Transcriptase Inhibitors Anti-HIV Agents |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Seropositivity Saquinavir Ritonavir HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Atazanavir Retroviridae Infections Immunologic Deficiency Syndromes |
Anti-Infective Agents RNA Virus Infections HIV Protease Inhibitors Slow Virus Diseases Anti-HIV Agents Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Protease Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections |